|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Manfredi S, Lepage C, Hatem C, Coatmeur O,
Faivre J and Bouvier AM: Epidemiology and management of liver
metastases from colorectal cancer. Ann Surg. 244:254–259. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramia JM, Lopez-Andujar R, Torras J, et
al: Multicentre study of liver metastases from colorectal cancer in
pathological livers. HPB (Oxford). 13:320–323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martinez-Outschoorn UE, Lin Z, Trimmer C,
et al: Cancer cells metabolically ‘fertilize’ the tumor
microenvironment with hydrogen peroxide, driving the Warburg
effect: implications for PET imaging of human tumors. Cell Cycle.
10:2504–2520. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hamaya K, Hashimoto H and Maeda Y:
Metastatic carcinoma in cirrhotic liver - statistical survey of
autopsies in Japan. Acta Pathol Jpn. 25:153–159. 1975.PubMed/NCBI
|
|
6
|
King PD and Perry MC: Hepatotoxicity of
chemotherapy. Oncologist. 6:162–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rubbia-Brandt L, Audard V, Sartoretti P,
et al: Severe hepatic sinusoidal obstruction associated with
oxaliplatin-based chemotherapy in patients with metastatic
colorectal cancer. Ann Oncol. 15:460–466. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kandutsch S, Klinger M, Hacker S, Wrba F,
Gruenberger B and Gruenberger T: Patterns of hepatotoxicity after
chemotherapy for colorectal cancer liver metastases. Eur J Surg
Oncol. 34:1231–1236. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cleary JM, Tanabe KT, Lauwers GY and Zhu
AX: Hepatic toxicities associated with the use of preoperative
systemic therapy in patients with metastatic colorectal
adenocarcinoma to the liver. Oncologist. 14:1095–1105. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ryan P, Nanji S, Pollett A, et al:
Chemotherapy-induced liver injury in metastatic colorectal cancer:
semiquantitative histologic analysis of 334 resected liver
specimens shows that vascular injury but not steatohepatitis is
associated with preoperative chemotherapy. Am J Surg Pathol.
34:784–791. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tamandl D, Klinger M, Eipeldauer S, et al:
Sinusoidal obstruction syndrome impairs long-term outcome of
colorectal liver metastases treated with resection after
neoadjuvant chemotherapy. Ann Surg Oncol. 18:421–430. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rizzo G and Fiorucci S: PPARs and other
nuclear receptors in inflammation. Curr Opin Pharmacol. 6:421–427.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peters JM, Shah YM and Gonzalez FJ: The
role of peroxisome proliferator-activated receptors in
carcinogenesis and chemoprevention. Nat Rev Cancer. 12:181–195.
2012.PubMed/NCBI
|
|
14
|
Dindo D, Demartines N and Clavien PA:
Classification of surgical complications: a new proposal with
evaluation in a cohort of 6336 patients and results of a survey.
Ann Surg. 240:205–213. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vauthey JN, Pawlik TM, Ribero D, et al:
Chemotherapy regimen predicts steatohepatitis and an increase in
90-day mortality after surgery for hepatic colorectal metastases. J
Clin Oncol. 24:2065–2072. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mehta NN, Ravikumar R, Coldham CA, et al:
Effect of preoperative chemotherapy on liver resection for
colorectal liver metastases. Eur J Surg Oncol. 34:782–786. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakano H, Oussoultzoglou E, Rosso E, et
al: Sinusoidal injury increases morbidity after major hepatectomy
in patients with colorectal liver metastases receiving preoperative
chemotherapy. Ann Surg. 247:118–124. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Di Paola R and Cuzzocrea S: Peroxisome
proliferator-activated receptors ligands and ischemia-reperfusion
injury. Naunyn Schmiedebergs Arch Pharmacol. 375:157–175. 2007.(In
Chinese). View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Braissant O, Foufelle F, Scotto C, Dauca M
and Wahli W: Differential expression of peroxisome
proliferator-activated receptors (PPARs): tissue distribution of
PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology.
137:354–366. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vidal-Puig AJ, Considine RV, Jimenez-Linan
M, et al: Peroxisome proliferator-activated receptor gene
expression in human tissues. Effects of obesity, weight loss, and
regulation by insulin and glucocorticoids. J Clin Invest.
99:2416–2422. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Naishadham D, Lansdorp-Vogelaar I, Siegel
R, Cokkinides V and Jemal A: State disparities in colorectal cancer
mortality patterns in the United States. Cancer Epidemiol
Biomarkers Prev. 20:1296–1302. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kong L, Ren W, Li W, Zhao S, Mi H, Wang R,
Zhang Y, Wu W, Nan Y and Yu J: Activation of peroxisome
proliferator activated receptor alpha ameliorates ethanol induced
steatohepatitis in mice. Lipids Health Dis. 10:2462011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Akiyama TE, Nicol CJ, Fievet C, et al:
Peroxisome proliferator-activated receptor-alpha regulates lipid
homeostasis, but is not associated with obesity: studies with
congenic mouse lines. J Biol Chem. 276:39088–39093. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stienstra R, Mandard S, Patsouris D, Maass
C, Kersten S and Muller M: Peroxisome proliferator-activated
receptor alpha protects against obesity-induced hepatic
inflammation. Endocrinology. 148:2753–2763. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Okaya T and Lentsch AB: Peroxisome
proliferator-activated receptor-alpha regulates postischemic liver
injury. Am J Physiol Gastrointest Liver Physiol. 286:G606–G612.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pozzi A, Ibanez MR, Gatica AE, et al:
Peroxisomal proliferator-activated receptor-alpha-dependent
inhibition of endothelial cell proliferation and tumorigenesis. J
Biol Chem. 282:17685–17695. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grau R, Diaz-Munoz MD, Cacheiro-Llaguno C,
Fresno M and Iniguez MA: Role of peroxisome proliferator-activated
receptor alpha in the control of cyclooxygenase 2 and vascular
endothelial growth factor: involvement in tumor growth. PPAR Res.
2008:3524372008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kaipainen A, Kieran MW, Huang S, et al:
PPA Ralpha deficiency in inflammatory cells suppresses tumor
growth. PLoS One. 2:e2602007. View Article : Google Scholar : PubMed/NCBI
|
